Table of Contents Author Guidelines Submit a Manuscript
International Journal of Nephrology
Volume 2013, Article ID 818537, 4 pages
Research Article

Transplant Outcomes in Patients with Idiopathic Membranous Nephropathy

1Department of Nephrology, Beaumont Hospital, Dublin 9, Ireland
2Department of Histopathology, Beaumont Hospital, Dublin 9, Ireland

Received 29 November 2012; Revised 1 February 2013; Accepted 1 February 2013

Academic Editor: Alessandro Amore

Copyright © 2013 Claire Kennedy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Background. The natural history of idiopathic membranous nephropathy and recurrent disease in transplants is variable. We performed a retrospective cohort study of renal transplant recipients with a primary diagnosis of idiopathic membranous nephropathy. We aimed to establish patterns of disease recurrence and to identify factors associated with disease recurrence. Methods. We accessed the Irish renal transplant database to identify patients with biopsy-proven idiopathic membranous nephropathy in receipt of a renal transplant between 1982 and 2010. A detailed medical chart review was performed in all cases, and a senior renal histopathologist reviewed all histology specimens. Results. The outcomes of 32 patients, in receipt of 36 grafts, are reported. There was a male preponderance ( ). Significant graft dysfunction, directly attributable to recurrent disease, was evident in 31% of cases at 10 years. There was no significant association between time on dialysis, HLA mismatch, occurrence of rejection, and the development of recurrent membranous disease. One patient was retransplanted twice; all three grafts were lost to aggressive recurrent membranous disease. Conclusions. It remains difficult to identify those that will develop recurrent membranous nephropathy. Almost one third of patients in this cohort developed clinically significant recurrent disease at 10 years.